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spectrophotometryAbstract Four rapid, reliable and economical spectrophotometric methods have been established
for the quantitative determination of Oseltamivir phosphate (OST) without the interference of
ascorbic acid (ASC) found in some of its counterfeit capsules. The ﬁrst method involves the use
of derivative spectrophotometry with the zero-crossing technique where OST was easily determined
using its 1D (Dk= 3) at 219 nm. The second method is based on a ﬁrst-order derivative ratio spec-
trophotometry (1DD, Dk= 5) where 218 nm was selected for its quantiﬁcation, while the third
method applies a more advanced spectrophotometric method based on the ratio difference spectro-
photometry (RD) in which the difference in absorbance ratio was measured between 217 and
210 nm. In the fourth method, difference spectrophotometric method (DA) is applied by subtracting
absorbance at 252 from that at 263 nm where the difference in absorbance was zero for ASC. The
proposed methods were validated for linearity, accuracy, precision and selectivity. Synthetic mix-
tures of different proportions and commercial capsules were assayed by the proposed methods
and the results revealed good accuracy and repeatability of the developed methods.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
OST (Ethyl (3R, 4R, 5S)-4-acetamido-5-amino-3-(1-ethylprop-
oxy)-1 cyclohexene-1-carboxylate phosphate; Fig. 1a) is a pro-
drug of Oseltamivir carboxylate, an inhibitor of the enzyme
neuraminidase, which has a role in the infectivity and replication
of inﬂuenza A and B viruses. It is used orally as capsules or sus-
pension for the treatment and post-exposure prophylaxis of
inﬂuenza A and B.1
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Figure 1 Chemical structure of OST (a) and ASC (b).
64 R.M. Youssef et al.OST recently becameofﬁcial in theUSP20112which describes
the HPLC method for its assay in bulk powder as well as in cap-
sules. Some spectrophotometricmethods3–5 were reported for the
assay of OST. HPLC methods were described for the analysis of
OST both in bulk and in commercial pharmaceuticals.6–8 Also a
selectiveHPLCmethodwas applied to evaluate potentially coun-
terfeitOSTcapsules.9FewHPLCmethodsweredeveloped for the
assay of OST in biological ﬂuids using liquid chromatography
coupled to tandem mass spectrometry.10,11 Other methods were
applied to its quantiﬁcation in its capsules like spectroﬂuorime-
try12 and capillary electrophoresis.13 A new HPTLC method
was recently developed for the evaluation of such OST counter-
feited pharmaceutical formulations.14
The specter of an avian inﬂuenza pandemic has given OST
much notoriety, and anticipation of the potential public health
threat has prompted a demand for its pharmaceutical prod-
ucts. Consequently, criminal elements have already produced
counterfeit OST preparations and speciﬁc cases of the seizure
were observed in the United Kingdom of 5000 counterfeit
packets of the OST products.15 Also, ASC (Fig. 1b) was re-
ported widely in counterfeit OST products which lacked the
active ingredient. These products had been purchased through
the internet and easily have gone unnoticed in the developing
countries, where insufﬁcient analytical resources hamper the
ability to monitor and preserve drug quality.16 This work de-
scribes the application of derivative, derivative ratio, ratio dif-
ference and difference spectrophotometry for the quantitative
estimation of OST in the presence of ASC. The proposed
methods do not require solving equations or working with
additional sophisticated software. In addition, the methods
are direct, inexpensive and do not need separation, speciﬁc
detectors or pretreatment steps enabling its application in
quality control analysis of OST in its capsules.
2. Experimental
2.1. Instruments
UV/Visible spectrophotometric measurements were carried
out using a Shimadzu Model1800 ultraviolet–visible
spectrophotometer.
2.2. Materials and reagents
OST was obtained from The Nile Company for Pharmaceuti-
cals and Chemical Industries (Cairo, Egypt) while ASC wasobtained from El-Borg (Alexandria, Egypt). Taminil-N cap-
sules were purchased locally. Analytical-grade methanol was
from S.D. Fine Chemicals (Mumbai, India).
2.3. Standard solutions
Stock standard solutions of 1000 lg mL1 OST or ASC were
prepared in methanol. The standard solutions were appropri-
ately diluted to prepare the working standard solutions using
methanol.
2.4. Construction of calibration curves
For 1D method, aliquots from the working standard solu-
tion of OST, within the concentration range listed in Ta-
ble 1, were accurately transferred into a set of 10-mL
volumetric ﬂasks. Dilution was made to volume with meth-
anol and the absorption spectra for each solution were re-
corded against methanol as a blank. The 1D amplitudes
were measured at 219 nm (zero-crossing of ASC) and plot-
ted against the concentrations of OST where a linear rela-
tionship is obtained.
Furthermore for the 1DD method, the absorption spectra
were divided (amplitude by amplitude at each wavelength)
by the spectrum of a 5-lg mL1 solution of ASC. The values
of 1DD amplitudes were measured at 218 nm and were found
proportional to the concentrations of OST.
In the RD method, the difference between the amplitudes
of the ratio spectra at 220 and 217 or 210 were plotted versus
the corresponding concentrations and the regression equations
were computed.
Moreover, in the DA method, OST was determined by plot-
ting the difference in absorbance values at 236 and 252 nm (the
difference is zero for ASC) against its corresponding
concentration.
2.5. Assay of capsules
The contents of ten capsules of Taminil-N were carefully evac-
uated, mixed and weighed. An accurately weighed amount of
the powder equivalent to 50 mg OST was transferred to a
50-mL volumetric ﬂask. A volume of 30 mL of methanol
was added and the ﬂask was sonicated for 30 min, and then
completed to volume with methanol followed by ﬁltration.
Then, the procedures were carried out on the ﬁltrate as men-
tioned under construction of calibration curves.
Table 1 Regression and statistical parameters for the determination of OST using the proposed methods.
Parameters 1D 1DD RD DA
Linearity range (lg mL1) 10.00–50.00 10.00–50.00 10.00–50.00 10.00–50.00
LOQ (lg mL1) 10.00 10.00 10.00 10.00
LOD (lg mL1) 3.12 3.82 4.15 4.35
Intercept (a) 4.00 · 104 5.00 · 102 0.23 1.86 · 102
Slope (b) 2.40 · 103 4.28 · 102 0.14 9.67 · 103
Correlation coeﬃcient (r) 0.9990 0.9990 0.9990 0.9991
Sa 1.84 · 103 3.60 · 102 0.12 8.14 · 103
Sb 5.45 · 105 9.10 · 104 2.86 · 103 2.01 · 104
Sy/x 1.75 · 103 3.44 · 102 0.10 7.31 · 103
a/Sa 0.22 1.39 1.92 2.29
Sb
2 2.97 · 109 8.28 · 107 8.18 · 106 4.04 · 108
Sb% 2.27 2.13 2.04 2.08
F 1357.04 1547.24 1524.27 1659.66
Signiﬁcance F 4.40 · 105 3.62 · 105 3.70 · 105 3.25 · 105
Sa is standard deviation of intercept, Sb is standard deviation of slope, and Sy/x is standard deviation of residuals.
Figure 2 The absorption (a) and the ﬁrst derivative (b) spectra of
35 lg mL1 OST (––), 5 lg mL1 ASC (—) and their mixture (. . ..)
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OST is used for the treatment and post-exposure prophylaxis
of inﬂuenza A and B. Criminal elements have already pro-
duced counterfeit OST preparations. ASC was reported in
the WHO as a main adulterating agent used widely in counter-
feit OST products which lacked the active ingredient. These
products had been purchased through the internet and easily
have gone unnoticed in the developing countries, where insuf-
ﬁcient analytical resources hamper the ability to preserve drug
quality.16 Hence it is very important to develop analytical
methods which are not only accurate, precise, and rapid but
also simple and economic for the determination of the studied
drug in its pharmaceutical dosage form and this is the main
task of the developed spectrophotometric methods. The UV-
spectrophotometric methods have the advantages of saving
time and cost when compared to the chromatographic tech-
niques, also they do not require solving equations or working
with additional sophisticated software enabling their applica-
tion in pharmaceutical industry.
This work concerns with the development and validation of
four selective spectrophotometric methods, 1D, 1DD, RD and
DAmethods for the determination of the suggested drug (OST)
in the presence of adulterating agent (ASC).
3.1. 1D method
Fig. 1a shows a considerable overlapping between the
absorption spectra of OST and ASC in methanolic solution,
so direct spectrophotometry cannot be applied. Derivative
spectrophotometry is very useful in the resolution of signal
overlap or interference.17 The application of the 1D method
showed appropriate resolution between OST and ASC
spectra. Thus, OST could be determined in presence of its
counterfeit ingredient (ASC) by measuring 1D amplitudes at
219 nm which corresponds to zero-crossing point of ASC as
shown in Fig. 2b.
3.2. 1DD method
Themain disadvantages of the zero-crossingmethod are the risk
of small drifts in the working wavelengths and the fact that theworking wavelengths generally do not produce corresponding
peaks in the derivative spectrum.18 A correct choice of divisorin methanol.
66 R.M. Youssef et al.concentration is fundamental. If the concentration of the divisor
is increased or decreased, the resulting values of the derivative
ratio are proportionally decreased or increased with the conse-
quent variation in both the sensitivity and the range of linearity.
The absorption spectra of standard OST solutions were divided
(amplitude by amplitude at each wavelength) by the spectrum of
ASC of concentration 5 lg mL1 where ratio spectra were ob-
tained (Fig. 3a). Then, the ﬁrst derivative of the ratio spectra
was calculated as shown in Fig. 3b. From these ﬁgures, the
1DD amplitudes were measured at 218 nm.
3.3. RD method
The most striking feature of this method is its simplicity, rapid-
ity and accuracy. This is a newly developed method having the
ability for solving severely overlapped spectra without prior
separation meanwhile it does not require any sophisticated
apparatus or computer programs.
The utility of the RD method is to calculate the unknown
concentration of the component of interest present in a mix-
ture together with an unwanted interfering one.Figure 3 The absorption ratio spectra (a) and 1DD spectra (b) of
OST (10, 20, 30, 40 and 50 lg mL1) using 5 lg mL1 ASC as
divisor.For the determination of concentration of the component
of interest by this method, the only requirement is the
contribution of the two components at the two selected wave-
lengths where the ratio spectrum of interfering component
shows the same amplitudes (constant) whereas the component
of interest shows signiﬁcant difference in these two amplitude
values at these two wavelengths with concentration. Ratio
spectra were obtained as mentioned in the 1DD method
(Section 3.2) and then amplitudes at 217 and 210 nm were
selected and subtracted (Fig. 3a).
3.4. DA method
The developed dual wavelength method provides a simple
method for the selective determination of OST using its zero
order spectra. The principle of this method is that the absor-
bance difference at two points on the spectra is directly pro-
portional to the component of interest, independent of the
interfering component. The pre-requisite for this method is
the selection of two wavelengths where the interfering compo-
nent shows the same absorbance value while the component of
interest shows signiﬁcant difference in absorbance. Selection of
the suitable wavelengths plays an important role; hence differ-
ent wavelengths were tried. Using the absorbance values at 236
and 252 nm (where ASC has the same absorbance values as
shown in Fig. 2a) gave the best selectivity when used for the
determination of OST.
4. Validation
ICH guidelines19 for method validation were followed for the
developed methods.
4.1. Accuracy and precision
Solutions containing three different concentrations of OST,
within the linearity range, were analyzed in ﬁve replicatesTable 2 Evaluation of the precision and accuracy of the
proposed methods for the determination of OST.
Methods Added concentrationa Found ± RSD%b Er%
c
1D method 20.00 100.30 ± 1.52 0.30
30.00 100.91 ± 0.93 0.91
40.00 101.18 ± 1.27 1.18
Mean 100.80 ± 1.24 0.80
1DD method 20.00 98.64 ± 1.50 1.36
30.00 99.09 ± 1.14 0.91
40.00 100.97 ± 0.83 0.97
Mean 99.57 ± 1.16 0.43
RD method 20.00 101.40 ± 0.87 1.40
30.00 101.92 ± 1.06 1.92
40.00 98.88 ± 0.90 1.12
Mean 100.73 ± 0.94 0.73
DA method 20 98.70 ± 1.58 1.30
30 101.06 ± 0.61 1.06
40 99.27 ± 1.80 0.73
Mean 99.68 ± 1.33 0.32
a Final concentration in g mL1.
b Mean recovery ± relative standard deviation for ﬁve
determinations.
c Percentage relative error.
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with small relative standard deviations (RSD%) were ob-
tained, which indicated the high accuracy and precision of
both methods.
4.2. Selectivity
The selectivity of the proposed methods was checked by ana-
lyzing synthetic mixtures containing different ratios of both
OST and ASC, where good percentage recoveries were ob-
tained indicating that ASC did not interfere with OST
(Table 3).
4.3. Limit of detection and limit of quantitation
LOD and LOQ were calculated using the formulae given by
Miller20 where the limit of detection, LOD= 3 S/b and the
limit of quantitation, LOQ= 10 S/b, where S is the standard
deviation of replicate blank responses (under the same condi-
tions as for sample analysis) and b is the sensitivity, namely
the slope of the calibration graph. Using the proposed meth-
ods, LOD and LOQ for each method were calculated and
are presented in Table 1.
4.4. Linearity
The linearity of the proposed methods was evaluated by ana-
lyzing series of different concentrations of OST. According
to ICH, at least ﬁve concentrations must be used. Under the
experimental conditions described, the graphs obtained by
plotting 1D, 1DD, RD and DA values at the speciﬁed wave-
lengths versus concentration (in the ranges stated in Table 1)
show linear relationships. The slopes, intercepts and correla-
tion coefﬁcients obtained by the linear least squares regression
treatment of the results are also given. An important statistical
parameter for indicating the random error in the estimatedTable 3 Evaluation of the proposed methods for the determination
Synthetic mixture number Nominal value (lg mL1)
OST ASC
1 10.00 5.00
2 10.00 10.00
3 20.00 10.00
Mean
SD
RSD%
Table 4 Statistical comparison for the determination of OST in its
Pharmaceutical preparation Found%± SDa
1D 1D
Taminil-N capsulesb 99.00 ± 1.73 10
tc 1.41 0.2
Fc 2.35 1.4
a Average of ﬁve determinations.
b Labeled to contain 75 mg OST per capsule (The Nile Co. For Pharm
c Theoretical value of T and F at p= 0.05 is 2.31 and 6.39, respectivelvalues of y is the standard error of the estimate, or the stan-
dard deviation about regression, or the standard deviation of
the residuals, Sy/x. The smaller the standard error of the esti-
mate the closer the points are to the straight line. Standard
deviation of intercept (Sa) and slope (Sb) is also presented
for each compound using the proposed methods of measure-
ments. The high values of the correlation coefﬁcients with neg-
ligible intercepts together with the high F-values indicate the
good linearity of the calibration graphs. The linearity was fur-
ther evaluated by calculation of the percentage relative SD of
the slope (Sb%). Also, the small degree of scatter of the exper-
imental data point around the line of regressions could be con-
ﬁrmed by the small values of the variances around the slopes
Sb.
2 For more conﬁrmation, the Student’s t-test was performed
to determine whether the experimental intercept (a) of the
above-mentioned regression lines was not signiﬁcantly differ-
ent from the null hypothesis. The calculated values of t (a/
Sa) do not exceed the 95% criterion of t= 2.31 for 5 samples.
So the intercepts are not signiﬁcantly different from zero in the
proposed methods. Thus, the hypothesis that (a) is of negligi-
ble value is conﬁrmed.20,21
For equal degrees of freedom, increase in F-values means
increase in the mean of squares due to regression and decrease
in the mean of squares due to residuals. The greater the mean
of squares due to regression, the more the steepness of the
regression line is. The smaller the mean of squares due to resid-
uals, the less the scatter of the experimental points around the
regression line is. Consequently, regression lines with high
F-values (low signiﬁcance F) are much better than those with
lower ones. Good regression lines show high values for both
(r) and (F) values.215. Assay of capsules
The proposed methods were applied to the determination of
OST in its commercial capsules. Satisfactory results wereof OST in its laboratory-prepared mixtures with ASC.
%Recovery
1D 1DD RD DA
98.41 97.73 101.62 97.86
99.00 99.26 99.89 98.67
97.91 99.52 101.91 100.29
98.44 98.84 101.14 98.94
0.55 0.97 1.09 1.24
0.56 98.14 1.08 1.25
pharmaceutical formulations using the proposed methods.
D RD DA
1.00 ± 2.65 100.57 ± 3.21 98.51 ± 2.44
3 1.14
7 1.73
aceuticals & Chemical Industries – Batch No. 10027).
y.
Table 5 Comparison between the proposed and reported spectrophotometric methods.
Method Reported
method3
Reported method4 Reported method5 Reported method12 Proposed methods
Method A Method B Method C Method I Method II 1D 1DD RD DA
k
(nm)
kmax
2085
kmax
530
kmax
545
kmax
512
kmax
520
kmax
590
kex 381 k
219
k
218
217–210 252–263
kem 483
Linearity
range (lg
mL1)
4–24 1–7 5–50 1–15 1.5–4.5 6–18 50–450* 10–50 10–50 10–50 10–50
Procedure The need of
waiting time of
10 min for the
reaction to be
completed
The formed
colored product is
stable only for
30 min
The need of
waiting time of
20 min with
heating at 70 C
for the reaction to
be completed
– The formed ion-pair complex
with OST was extracted with
ethyl acetate. (The ion-pair
extraction technique suffers
from difﬁculties & inaccuracies
arising from incomplete extrac-
tion or emulsion formation.)
– A buffer is required. (The
pH adjustment may vary
due to pH-meter calibra-
tion or personal variation
which affects the method
ruggedness)
– No use of toxic
or expensive solvents
– No care is needed
regarding the pH adjustment
– No need for extraction steps
– The proposed methods
are direct and not time
consuming
– The proposed methods determine
directly the concentration of OST
in presence of the ASC without any
interference with minimal cost and time.
On the other hand, the reported methods
determine OST only
– The reported methods require
the use of a buffer (The pH
adjustment may vary due to
pH-meter calibration or per-
sonal variation which affects
the method ruggedness.)
– The need of pretreatment
step with ﬂuorescamine
to give a ﬂuorescent
derivative
The used reagents (p-dimethyl amino cinnamaldehyde in
method A, 4-aminophenazone in method B or ferric
chloride and 1,10-phenanthroline in method C) add extra
cost
– The used reagents (congo red
in I or bromochlorophenol
blue in II) add extra cost
*Concentration in ng mL1
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(Table 4). Excellent percentage recoveries and SD suggested
that there is no interference from excipients, which are present
in OST capsules. Statistical analysis of the results obtained by
the proposed methods was performed using Student’s t-test
and the variance ratio F-test (Table 4). The calculated values
did not exceed the theoretical ones, indicating no signiﬁcant
difference between the performance of the compared methods
regarding accuracy and precision.
6. Conclusion
The proposed spectrophotometric methods have the advanta-
ges of saving time, cost and environmental protection without
sacriﬁcing accuracy when compared to the reported chromato-
graphic techniques, also they do not require solving equations
or working with additional sophisticated software enabling
their application in pharmaceutical industry. Table 5 shows
the comparison between proposed and reported spectrophoto-
metric methods. They can be considered selective and simple
enough to be applied in the quality-control analysis of the drug
without interference of the commonly encountered capsules
additives or ASC that is present in many of its counterfeit
pharmaceutical products.
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